Performance of FRAX in men with prostate cancer : A registry-based cohort study
Journal article
Ye, Carrie, Morin, Suzanne N., Lix, Lisa M., McCloskey, Eugene V., Johansson, Helena, Harvey, Nicholas C., Kanis, John A. and Leslie, William D.. (2023). Performance of FRAX in men with prostate cancer : A registry-based cohort study. Journal of Bone and Mineral Research. 38(5), pp. 659-664. https://doi.org/10.1002/jbmr.4793
Authors | Ye, Carrie, Morin, Suzanne N., Lix, Lisa M., McCloskey, Eugene V., Johansson, Helena, Harvey, Nicholas C., Kanis, John A. and Leslie, William D. |
---|---|
Abstract | The Fracture Risk Assessment Tool (FRAX®) was created to predict major osteoporotic fractures (MOF) and hip fractures in the general population. Whether FRAX accurately predicts fractures in men with prostate cancer is unknown. Our objective was to assess the performance of FRAX for predicting incident fractures in men with prostate cancer. Men from the Manitoba Bone Mineral Density (BMD) Registry (1996–2018) with prostate cancer diagnoses in the 3 years prior to dual‐energy X‐ray absorptiometry (DXA) were identified. FRAX scores with and without BMD were calculated. From population‐based healthcare data we identified incident MOF, hip fracture, any osteoporotic fracture and death from the date of BMD testing to March 31, 2018. Cox regression was performed to estimate hazard ratios (HRs) with 95% confidence intervals (95% CIs) per standard deviation increase in FRAX score. Observed 10‐year probability (estimated with competing risk of mortality) was compared with 10‐year FRAX‐predicted fracture probability to assess calibration. The study population included 684 men with prostate cancer (mean age 74.6 years) and 8608 men without prostate cancer (mean age 65.5 years). FRAX stratified risk for MOF (HR 1.91, 95% CI 1.48–2.45 with BMD; HR 1.96, 95% CI 1.43–2.69 without BMD) and hip fracture (HR 3.37, 95% CI 1.90–6.01 with BMD; HR 4.58, 95% CI 2.17–9.67 without BMD) in men with prostate cancer. There was no effect modification observed with prostate cancer status or current androgen deprivation therapy. Observed 10‐year fracture probability in men with prostate cancer showed good agreement with FRAX with and without BMD included in the calculation (observed/predicted calibration ratios MOF 0.97, hip 1.00 with BMD; MOF 0.92, hip 0.93 with BMD). In conclusion, FRAX reliably predicts incident fractures in men with prostate cancer. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). |
Keywords | fracture risk assessment; general population studies; DXA; cancer; osteoporosis |
Year | 2023 |
Journal | Journal of Bone and Mineral Research |
Journal citation | 38 (5), pp. 659-664 |
Publisher | Wiley Periodicals LLC |
ISSN | 0884-0431 |
Digital Object Identifier (DOI) | https://doi.org/10.1002/jbmr.4793 |
PubMed ID | 36807916 |
Scopus EID | 2-s2.0-85131436169 |
Open access | Published as ‘gold’ (paid) open access |
Page range | 659-664 |
Publisher's version | License File Access Level Open |
Output status | Published |
Publication dates | |
Online | 20 Feb 2023 |
Publication process dates | |
Accepted | 17 Feb 2023 |
Deposited | 02 May 2025 |
Additional information | © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
https://acuresearchbank.acu.edu.au/item/91v3x/performance-of-frax-in-men-with-prostate-cancer-a-registry-based-cohort-study
Download files
Publisher's version
OA_Ye_2020_Performance_of_FRAX_in_men_with.pdf | |
License: CC BY 4.0 | |
File access level: Open |
2
total views0
total downloads2
views this month0
downloads this month